Scientists at the University of Cambridge have created a new kind of vaccine; and for the first time ever, its key ingredient was designed entirely by artificial intelligence. The goal? To protect people not just from viruses we know today, but from ones that haven’t even infected humans yet.
Here’s the problem with most vaccines: viruses like COVID-19 and the flu constantly change their appearance, or “mutate.” That forces scientists to update vaccines regularly, and they’re often playing catch-up. This new approach tries to get ahead of the problem entirely.
The AI model used studied genetic data from a wide range of coronaviruses (the same family that includes COVID-19) and designed what researchers call a “super-antigen.” Think of an antigen like a wanted poster for your immune system. Instead of showing your body just one virus to watch for, this super-antigen teaches it to recognize an entire family of viruses, even ones that could jump from animals to humans for the first time.
Early human trials involving 39 people showed the vaccine appears to be safe. A larger study with around 200 participants is now underway to see how well it trains the immune system. Results so far are described as “modest but exciting.” The Cambridge team is already working on similar vaccines for the seasonal flu, bird flu, and Ebola.
For Canadians, this research carries real weight. Canada was deeply affected by COVID-19, and public health experts have long warned that the next pandemic is a matter of “when,” not “if.” A universal, AI-designed vaccine could reduce the scramble for new shots every outbreak, ease pressure on Canada’s healthcare system, and potentially save thousands of lives. These benefits would particularly be realized among older Canadians and those in remote or Indigenous communities with limited healthcare access.
To read more on this story, click here.
This page is also available in:
Français
